Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 3989-3996

  Baudrand, Rene ^a   Guarda, Francisco J ^a   Torrey, Jasmine ^b   Williams, Gordon ^b   Vaidya, Anand ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN; SODIUM INTAKE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; SODIUM RESTRICTION; URINARY EXCRETION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ALGORITHM; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DIET THERAPY; DOWN REGULATION; FALSE NEGATIVE RESULT; HYPOVENTILATION; MASS SCREENING; MIDDLE AGED; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, CENTRAL; SODIUM INTAKE; URINE;

ADULT; ALDOSTERONE; ALGORITHMS; COHORT STUDIES; DIAGNOSTIC ERRORS; DIET, SODIUM-RESTRICTED; DOWN-REGULATION; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; HYPERTENSION; HYPOVENTILATION; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RENIN; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, CENTRAL; SODIUM, DIETARY;

EID: 84994829883     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1963     Document Type: Article

References (29)

1. Williams JS, Williams GH, Raji A, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2006;20:129-136.
2. Funder JW. Primary aldosteronism and low-renin hypertension: a continuum? Nephrol Dial Transplant. 2013;28:1625-1627.
3. VongpatanasinW.Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311:2216-2224.
4. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172:R191-R203.
5. Hanslik G, Wallaschofski H, Dietz A, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. Eur J Endocrinol. 2015;173:665-675.
6. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016:101:1889-1916.
7. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012; 44:170-176.
8. Raizman JE, Diamandis EP, Holmes D, Stowasser M, Auchus R, Cavalier E. A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. Clin Chem. 2015;61:1022-1027.
9. Lalli E, Barhanin J, Zennaro MC, Warth R. Local control of aldosterone production and primary aldosteronism. Trends Endocrinol Metab. 2016;27:123-131.
10. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res. 2011;34:98-102.
11. Vaidya A, Underwood PC, Hopkins PN, et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013;61:886-893.
12. Baudrand R, Pojoga LH, Vaidya A, et al. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation. 2015;132:1825-1833.
13. Pimenta E, Stowasser M, Gordon RD, et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013;143: 978-983.
14. Rye P, Chin A, Pasieka J, So B, Harvey A, Kline G. Unadjusted plasma renin activity as a "first-look" test to decide upon further investigations for primary aldosteronism. J Clin Hypertens (Greenwich). 2015;17:541-546.
15. Young WF Jr, Hogan MJ, Klee GG, Grant CS, van Heerden JA. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc. 1990;65:96-110.
16. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich). 2006;8:887-893.
17. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586-613.
18. Koch M, Aker S, Haastert B, Rump LC. Clinical relevance of dietary salt intake on aldosterone and the aldosterone-to-renin ratio as screening parameters for primary aldosteronism. Clin Nephrol. 2010;74:182-189.
19. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386-394.
20. Cogswell ME, Mugavero K, Bowman BA, Frieden TR. Dietary sodium and cardiovascular disease risk-measurement matters [published online ahead of print June 1, 2016)]. N Engl J Med. doi: 10.1056/NEJMsb1607161.
21. Antman EM, Appel LJ, Balentine D, et al. Stakeholder discussion to reduce population-wide sodium intake and decrease sodium in the food supply: a conference report from the American Heart Association Sodium Conference 2013 Planning Group. Circulation. 2014; 129:e660-e679.
22. Tanaka T, Okamura T, Miura K, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16:97-103.
23. Brown JM, Underwood PC, Ferri C, et al. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertension. 2014;63:1205-1211.
24. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
25. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846-856.
26. Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2012;26:485-495.
27. Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab. 2010;95:2296-2305.
28. Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA. 2015;112:E4591-E4599.
29. Nanba K, Chen AX, Omata K, et al. Molecular heterogeneity in aldosterone-producing adenomas. J Clin Endocrinol Metab. 2016; 101:999-1007.